where recombinant MAGE-A3 with AS15 immunostimulant were administered to 13 MM subjects pre- and post-ASCT in conjunction with early post-SCT vaccine-primed autologous lymphocyte infusion. This evidence concerns the gene MAGEA3 and Miyoshi myopathy.